Speakers

Mr. Berns was appointed to the role of Anacor Pharmaceuticals President and Chief Executive Officer in 2014. He has served as a member of the Board of Directors since 2012 and as Chairman of the Board of Directors since 2013. Anacor was acquired by Pfizer in June 2016. From August 2012 to March 2014, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From March 2006 to September 2012, Mr. Berns served as President and Chief Executive Officer and as a member of the board of directors of Allos Therapeutics, Inc. which was acquired by Spectrum Pharmaceuticals, Inc. in September 2012.

From July 2005 to March 2006, Mr. Berns was a self-employed consultant to the pharmaceutical industry. From June 2002 to July 2005, he was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in July 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology, and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, which was acquired by Abbott in 2001. From 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. He has been a director of Jazz Pharmaceuticals, PLC since June 2010. Mr. Berns received a B.S. in Economics from the University of Wisconsin.

Robert Bitterman founded Cutanea Life Sciences Inc. in September 2005 as its President, Chief Executive Officer, and Board Director. Mr. Bitterman has had an extensive and successful career in the pharmaceutical industry achieving various milestones, most notably, the sale of Cutanea to Maruho Company Ltd. in February 2012. Maruho is a privately owned Japanese dermatology-focused pharmaceutical company which celebrated its 100th year anniversary in October of 2015. During his tenure he has successfully transacted two proprietary technology license agreements in addition to acquiring a third technology and a commercially ready to market product. These form the foundation of Cutanea’s development and commercial operations for future value creation.

Mr. Bitterman also served as President and General Manager of Dermik Laboratories, the global dermatology strategic business unit of Aventis S.A. from 1994 into 2004. Under his direction Dermik secured FDA approval for six NDA’s (New Product Approvals) and one PMA, a class 3 medical device. He also directed eight commercial product launches in the U.S. and several product launches in other international markets. Mr. Bitterman was also responsible for constructing and directing an operating joint venture in the People’s Republic of China. During his ten year tenure at Dermik Laboratories he led his team in achieving average sales and EBITA growth of 21% and 24%, respectively. Prior to assuming senior operational leadership positions, Mr. Bitterman held various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. He has also held the position of President and Chief Executive Officer of Isolagen, Inc. from September 2004 until April 2005.

Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Human Letters (Honoris Causa) from the New York College of Podiatric Medicine and is a member of the Philadelphia Business Leaders Network.

He also serves as a director on the Board of Directors of Rxi Pharmaceutical Corporation

Dan Browne has been the co-founder, President and Chief Executive Officer of Revance Therapeutics, Inc. (NASDAQ; RVNC), since the company's inception. Revance's science and competitive advantage is based upon a proprietary NCE peptide technology, which when combined with active biologic molecules, delivers improved patient outcomes. Under his leadership as CEO, the Company has grown from a single idea to a portfolio of late-stage Phase 3 and Phase 2 biologic products for aesthetic medicine and underserved therapeutic specialties, including dermatology, neurology and orthopedics. He has led the Company’s growth over five rounds of private capital totaling more than $200 million; a $110 million IPO and a $140 million follow-on financing in 2014 and a $134 million in 2015.

Prior to Revance, Mr. Browne held a variety of senior executive operation roles with a global medical device company, W.L. Gore & Associates, Inc (GORE-TEX® Medical Products). and venture-backed companies, Prograft Medical Inc. (acquired by W.L Gore & Associates, Inc.) and Neomend, Inc. (acquired by CR Bard). Mr. Browne has over 20 years' experience, holding senior executive level positions in product development, commercial operations, and corporate development.

Mr. Browne received his B.S. from the University of Hawaii and an M.B.A from Pepperdine University.

Chris Chapman is Vice President and General Manager for the U.S. Prescription Business of Galderma, the medical solutions business of Nestlé Skin Health. As the leader of the company’s largest prescription business globally, Chris manages Galderma’s broad portfolio of prescription medications including the full line of products that treat acne, psoriasis, eczema and rosacea. He also oversees Galderma® CareConnect, a patient savings card program that offers discounts to patients on the quality dermatology prescription medications offered by Galderma.

Chris joined Galderma in 2015, and in his previous position as Vice President of Strategic Access was responsible for commercial payer account management and contracting, trade account management and branded consumer rebate programs. During his tenure, Chris developed and launched the Galderma® CareConnect program. The program has grown to more than 46,000 pharmacies and served more than 790,000 unique patients, and has filled more than 1,400,000 prescriptions. In 2017 Galderma® CareConnect program was a Silver Winner in the PMC360 Magazine Trailblazer Awards in the Persistence/Adherence Program category.

Prior to joining Galderma, Chris spent 20 years at Pfizer in roles of increasing responsibility, including leading the U.S. Pharmaceutical Contracting and Pricing Organization, the South Regional Payer Prescription Business, National Healthcare Operations National Account Management Team and numerous leadership roles throughout the organization.

Chris also served as the Executive Director of Managed Markets and Contracting for Medicis Pharmaceutical Corporation, in addition to co-founding and serving as the Senior Principal of The Core Access Group, a biopharmaceutical consulting firm dedicated to the development of data driven market access strategies and enabling technologies.

Chris holds a Bachelor of Science from Towson University in Maryland and is an active member of the Phi Alpha Theta International Honor Society for History.

Dr. Noah Craft MD, PhD is the co-founder and CEO of Science 37 and a physician-scientist-entrepreneur. Science 37 transforms the clinical research process, accelerating biomedical discovery and reducing clinical trial costs by shifting the center for research from traditional institutional investigative sites to the patient’s home and local healthcare system. We use our patient-centered technology platform (NORA®) to create metasites™, simplify the process of participating in trials, and connect patients safely and securely to the world’s best scientists, no matter where they live. For 10+ years Dr. Craft has worked on the skin microbiome, parasite immunology, and cancer vaccine development. He also serves as a senior strategic advisor to both VisualDx and Direct Derm. He has published more than 45 peer-reviewed research manuscripts and holds multiple patents.

Dr. Craft received a B.S. from Brown University, completed medical school, residency, and post-doctoral research at UCLA.

Mrs. Cronholm was recently appointed to the role of President and CEO of Cytrellis, she previously headed up the company’s marketing efforts. Cytrellis is a venture backed, clinical stage medical technology company developing a new, proprietary class of aesthetic devices. Cytrellis’ devices are designed to remove micro sized cores of sagging skin without surgery or scarring.

Mrs. Cronholm has more than 20 years' experience in the life sciences and medical device industry. She managed the body contouring franchise at Cynosure, directed marketing and product management of several product lines. Prior to joining Cytrellis, Mrs. Cronholm was Head of Marketing for the Lab Solutions business at EMD Millipore. Through her 12 year tenure at EMD Millipore she held various roles such as marketing manager, research and development scientist, and quality manager. She began her career in the biotech industry working at TransKaryotic Therapies.

Karen has a B.S. in Microbiology from the University of New Hampshire and earned an M.B.A. with honors from Northeastern University.

Ruth Dovdavany is currently the Vice President of Marketing within the Inflammation and Immunology Business Unit at Pfizer, where she has been for over 13 years. Ruth has over 15 years of marketing experience across physician, consumer and payer stakeholders. Ruth has been a part of some of Pfizer's flagship brands including Zyrtec, Viagra and Lyrica. In addition, Ruth has extensive experience leading product launches. She led Pfizer's Eliquis launch across three indications in the U.S., had an opportunity to be the Head of Marketing for the US Cardiovascular Franchise at Novartis and led the launch of Entresto and is now, back at Pfizer, leading Pfizer's entre into Dermatology with the launch of Eucrisa.

Ruth graduated from Brown University with a Bachelor of Arts in Business Economics and 20th Century European History and received her Master of Business Administration from Harvard Business School. Ruth lives in Millburn, NJ with her family.

Brett Fair brings more than 19 years of pharmaceutical commercialization and global business development experience to his position as Senior Vice President, Commercial Operations at Aclaris Therapeutics. Before joining Aclaris, Mr. Fair was the Vice President of Business Development at Aqua Pharmaceuticals, LLC. Prior to Aqua Pharmaceuticals, LLC, Mr. Fair held global commercial and business development roles at GlaxoSmithKline plc. He started his career at Allergan plc and held positions of increasing responsibility in sales and marketing.

Mr. Fair received his Bachelor of Science from the University of Delaware and his Master of Business Administration from the Graziadio School of Business and Management at Pepperdine University.

Mark Foley served as Chairman, President & Chief Executive Officer of ZELTIQ Aesthetics (ZLTQ) up and through the Company’s acquisition by Allergan (AGN) for $2.5B in April of 2017. In April of 2012, Mr. Foley stepped in from the board to become ZELTIQ’s interim CEO and then in August of 2012 he was named the company’s permanent CEO. Over the next 5 years, he led the company’s growth from $68M in annual revenue to over $350M in 2016 by consistently growing top line revenue by approximately 40% YoY while also delivering 16 straight quarters of top line beat and raise revenue performance. During his leadership, the company’s stock price grew from a low of $3.50 to $56.50 at the time of acquisition while the Company’s employee base grew to over 700 people worldwide. In 2017, Mark was recognized by Healthegy as the MedTech DealMaker of the year.

Mr. Foley currently serves as a Managing Director at RWI Ventures and as a board member for Glaukos (GKOS). He also serves as Chairman of ULab where he was a founding investor.

Prior to this, Mr. Foley held a variety of operating roles in large public companies and venture-backed startups including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where he was the founder and CEO. Mr. Foley has over 25 years of medical device operating, investment and CEO experience. Additionally, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new companies. Mr. Foley serves or has served as a Senior Advisor, Executive Chairman, interim CEO and Board Member for a number of medical device companies.

Mr. Foley received his B.A. from the University of Notre Dame and is a named inventor on over 13 patents.

Dr. Bhushan Hardas joined Almirall as Executive Vice President of R&D, Chief Scientific Officer and a member of the Management Board. Bhushan has trained in Molecular biology and dermatology and received an MBA in health care management. He was trained in Kings College London and the University of Michigan and has over 20 years of professional experience in Pharmaceutical industry in Dermatology and Medical Aesthetics, including Merz Pharmaceuticals in the US, with his last position there as Senior VP and CSO North America and Global Head of R&D for Dermatology. He has served as Chief Medical Officer (Devices) and Global Head of R&D Dermatology and Medical Aesthetics for Allergan, based in Irvine, California. His has extensive experience and knowledge in dermatology and medical aesthetics towards generating new innovative projects as well as providing expert advice on potential business development opportunities and external innovation.

Bill Humphries joined Valeant Pharmaceuticals on January 2, 2017 as Executive Vice President, Company Group Chairman for Ortho Dermatologics and OraPharma. Bill has more than 30 years of experience in the specialty pharmaceutical industry, with more than 26 of those years focused on the commercialization of dermatology specialty pharmaceutical products globally.

Previously Bill was appointed CEO of Merz North America in March 2012, where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals, LLC, Merz Aesthetics, Inc. and Merz Pharma Canada, Ltd. Bill also served on the Merz Pharma Board and was the Chairman of the Merz, Inc. Board of Directors.

Prior to joining Merz, Bill served as the President of Stiefel, a leader in global dermatology and skin health, where he spearheaded two major acquisitions, and led the global integration of Stiefel into GlaxoSmithKline. In August 2009, Bill was appointed President of Stiefel, a GSK company, after GlaxoSmithKline (GSK) successfully acquired Stiefel Laboratories in July 2009 for $3.6 billion dollars. Bill was a key leader in this transaction and the commercial lead for the global integration of Stiefel into GSK. From April 2008 to August 2009, Bill served as President of Stiefel Laboratories.

Previously, Bill was Senior Vice President, US Commercial Operations and Chief Commercial Officer. Beginning in April 2006, he served as a member of the Company’s Board of Directors. Bill was a key leader in two major acquisitions for Stiefel: Barrier Therapeutics, Inc., which completed in 2008, and Connetics Corporation, which completed in 2006. During his tenure at Stiefel, Bill spearheaded the development of the company’s global commercial infrastructure, commercialization of its product portfolio, and managed worldwide operational initiatives.

From 1996 to 2004, Bill served in numerous executive roles in sales and marketing, business development, and international marketing for Allergan, Inc. He completed his tenure with Allergan, Inc. as Vice President US Skin Care, where he successfully led the Skin Care business back to profitable growth and was a key colleague in the launch of Botox Cosmetic to Dermatologists.

Bill currently serves on the Board of Clearside Biomedical, is the Chair of the North Carolina State University Global Luxury Management Board and serves on the Aclaris Therapeutics Board. Bill received a Master’s degree in Business Administration from Pepperdine University in Malibu, California. He completed his undergraduate studies at Bucknell University in Lewisburg, Pennsylvania, earning a Bachelor of Arts degree.

Vince Ippolito has over 30 years of experience in the pharmaceuticals industry, including 20 years in dermatology and aesthetic medicine. He most recently served as the Chief Commercial Officer Executive Vice President of Anacor Pharmaceuticals until Sept 2017, where he was responsible for developing marketing and sales functions, as well as strategizing the company’s product portfolio. Previously, Mr. Ippolito was Executive Vice President and Chief Commercial Officer at Medicis, a leading dermatology and aesthetic medicine company, who brought Restylane and Dsyport to Market in the US. Throughout his career, he has launched more than 20 brands in dermatology and aesthetic medicine. He took a leading role in two of the largest dermatology acquisitions in the past five years totaling $7.8 billion.

Mr. Ippolito holds a B.A. in Business Administration, Management, and Operations from the University of Wisconsin and a minor in East Asian Studies from Sophia University in Japan.

Deborah Kilpatrick, PhD is the CEO of Evidation Health, a digital health company backed by B Capital Group, GE Ventures, Sanofi Ventures, Asset Management Ventures, and Rock Health. Evidation Health quantifies real life health outcomes in the digital era of medicine using connected device data streams across therapeutic areas.

Prior to her role at Evidation Health, Deborah was the Chief Commercial Officer of genomic diagnostics company CardioDx, whose Corus CAD product was named in the Wall Street Journal Technology Innovation Awards and TIME Magazine's Top 10 Medical Breakthroughs. Earlier in her career, Deborah held multiple leadership roles at Guidant Corporation, including Research Fellow, Director of R&D, and Director of New Ventures in the Vascular Intervention Division. She is a Fellow of the American Institute of Medical and Biological Engineering and is a co-founder of the MedtechVision Conference now held annually in Silicon Valley.

Deborah holds B.S., M.S. and Ph.D. degrees in engineering, with a minor in applied mathematics and statistics, from Georgia Tech.

Ron Marchessault is Vice President of Value and Access for Sanofi Genzyme's Specialty Care Division.

Since 2016 he has been responsible for the overall market access strategy for the Multiple Sclerosis, Oncology, and Immunology franchises. Ron brings expertise in overseeing and leading the organizational development and implementation of product value propositions, marketing campaigns, and integration of contracting approaches across payer channels.

Ron joined Genzyme in 2002 as Vice President of Sales in the Rare Genetic Diseases Business Unit and moved into the role of Vice President of Market Access in 2006 supporting the access needs for the Genzyme (Sanofi Genzyme) Franchises.

Before joining Genzyme, Ron worked for Novartis Pharmaceuticals where he had more than 18 years of sales, managed care and management experience in the transplant, neuroscience, cardiovascular and dermatology areas.

Ron is a graduate of The University of Massachusetts with a BB A in Marketing

Alex Martin joined Realm Therapeutics in June 2015 as Chief Executive Officer and Executive Director. He brings nearly 30 years of experience as a senior executive in private and public biopharmaceutical companies. He previously served as Chief Executive Officer of Affectis Pharmaceuticals AG, Chief Operating Officer of Intercept Pharmaceuticals (NASD: ICPT), and Chief Financial Officer at BioXell S.p.A., which was acquired by Cosmo Pharmaceuticals S.A. Mr. Martin began his career at SmithKline Beecham Pharmaceuticals before joining Novartis as Vice President, Global Business Development & Licensing. Most recently, he served as President of moksha8, a leading Latin American specialty pharmaceutical company. In his various roles, he has built teams, raised multiple rounds of capital and closed transformative deals with world-class companies. Mr. Martin holds a BA from Cornell University and an MBA from The Harvard Business School.

Raymond A. Miller is a partner and co-chair of the Intellectual Property Department of Pepper Hamilton LLP, resident in the Pittsburgh office. Mr. Miller is co-chair of the firm’s Life Sciences practice group and a member of the firm’s Executive Committee. A registered patent attorney, Mr. Miller focuses his practice on identifying, protecting, securing and maximizing the value of clients’ intellectual property.

Mr. Miller’s clients include universities, research institutes and businesses ranging from idea stage through Fortune 500 companies, as well as other organizations and individuals involved in basic research and technology transfer. He has represented Ivy League universities, research organizations, pharmaceutical companies, biotechnology companies, consumer products companies, manufacturing companies, computer software developers and R&D contractors. His practice includes both prosecution and transactional IP, including acquiring and licensing patents, trademarks, copyrights and trade secrets, as well as litigation.

Mr. Miller’s practice includes an array of chemical, medical, pharmaceutical, mechanical, environmental and business method fields. While he is particularly adept at handling technologies in the life sciences, he also is proficient in areas of material sciences, metallurgy, thin-film technology, specialty chemicals, polymer chemistry, nanotechnology and cosmetics.

Mr. Miller is a member of the American Association for the Advancement of Science, the Association of University Technology Managers, Inc. and the American Intellectual Property Law Association. He has written and presented numerous scientific and legal publications.

Venkat comes with a very rich and global experience of more than 25 years, successfully leading organizations in the biotech and cosmoceutics businesses. He held top management roles in the biotech and pharmaceutical companies like Shantha Biotechnics (A Sanofi Company) and Aurobindo Pharma and he immensely contributed to their all-round growth. He was instrumental in creating market focus and orchestrating vaccine portfolio strategy in Shantha Biotech - a biosimilar and vaccine company, and it was eventually acquired by Sanofi for $800 million USD. He has been a part of significant revenue growth and value creation in Aurobindo Pharma in the global business segment of APIs and finished dosage form products in multiple therapy areas.

He has held CEO and President roles in Emami and Cavinkare, cosmoceutical and consumer product companies in India with global operations, creating value and growing them significantly with an all rounded approach. During his stint at Emami (a listed company) as CEO, the company's market cap increased from $ 300 MN to $ 1.2 BN. During the early part of his career, he created some very successful Cosmoceutical brands in Cavinkare, and built the organization with a 10X revenue increase in 6 years’ time.

He comes with core strengths in Strategy, Innovation, Technology, Commercialization, Organization building, Finance, M&A. Venkat has received his B.Tech in Mechanical Engineering and an MBA from Indian Institute of Management – Ahmedabad, India.

Luis is a co-founder of Dermira and serves as Chief Development Officer. He has nearly 30 years of product development and portfolio management experience. Prior to joining Dermira, Luis served as Vice President, Head of Global Prescription Development at Stiefel, a GSK company, and was Senior Vice President Portfolio Planning and Management at Stiefel Laboratories prior to its acquisition by GlaxoSmithKline, Inc. He also held leadership roles in portfolio management and product development at Connetics and Theravance, Inc. as well as various positions in manufacturing and research and development at Genentech, Inc. Luis currently serves as an advisor to the SPARK program for the Stanford University School of Medicine.

Luis holds a B.S. in biochemistry from San Francisco State University.

June Lee Risser is Vice President and General Manager for the U.S. Nestlé Skin Health Consumer Care business. A strategic business leader with a passion for building great brands, June is responsible for leading the U.S. commercial organization for the Nestlé Skin Health portfolio of consumer-available brands including Cetaphil® Gentle Skin Care products, celebrating 70 years of healthy skin in 2017 and Differin® Gel, first FDA-approved, prescription-strength retinoid acne treatment available over the counter since 2017.

Mrs. Risser joined Galderma in April 2016 as Vice President of Marketing for the Consumer business. In that role, she redefined the strategy and streamlined the structure of the marketing team to drive stronger growth on the priority brands of Cetaphil and Differin.

Prior to joining Galderma, June spent 12 years with Reckitt Benckiser in roles of increasing responsibility. During her tenure there, she led key consumer brands such as Lysol and Clearasil to new heights. As Global Innovation Director for the Personal Care Category based in the U.K., she led strategic planning and innovation for Clearasil. Before that, June was a Managing Director in a brand strategy consulting firm in NYC, Vivaldi Partners, advising clients on marketing and growth strategies.

Mrs. Risser holds a bachelor’s degree, magna cum laude, from Princeton University and a master’s degree from the JFK School of Government at Harvard University.

Stephen Seuntjens holds a Masters in International Management and a Bachelor of Science in Business Administration, Accounting and has over 20 years of global experience in building and developing new businesses, both organically as well as through M&A (buy & sell). He has worked and lived in Minneapolis, Tel Aviv, London and Amsterdam. This experience includes both executive positions in multinationals as well as entrepreneurial endeavors. Companies he has supported include Mind CTI, and Israeli-based, Nasdaq-listed software billing provider; Shapeways, as US based portal company allowing creatives to realize their objects through 3D printing and Directlife, a Dutch company part of Royal Philips Electronics, motivating individuals to become more physically active through monitoring and coaching.

Prior to PHS Capital, Stephen Seuntjens was CEO of Philips Lifestyle Incubator. Lifestyle Incubator invests in both service and product concepts within the wellbeing / consumer health domain.

David Steinberg joined Jefferies as Managing Director and Senior Research Analyst covering the Specialty Pharmaceuticals sector in January 2014. Previously he was a Managing Director at Deutsche Bank (formerly Alex. Brown) for 15 years. David was one of the first analysts on Wall Street to identify Specialty Pharma as a major growth opportunity for the investment community. He has regularly been voted to the Institutional Investor "All American Research Team", including most recently in 2017. He has also been selected to the Wall Street Journal's "Best on the Street" survey for stock picking.

David's research on various topics within the global drug industry has been frequently referenced in such national publications as Barron's, The New York Times, and Fortune. David has been involved with numerous dermatology-/aesthetics-focused companies during his career. Selected companies he has covered include Aclaris, Allergan, Anacor, Collagenex, Medicis, Penederm, Perrigo, and Valeant.

David received a degree in Business Administration from Colby College and a Master of Business Administration from the Harvard Business School.

Dr. Emma Taylor is the CEO and co-founder of Naked Biome. She is a board-certified Dermatologist and Dermatopathologist, and fellow of the American Academy of Dermatology. She completed her residency and fellowship training at UCLA and stayed on as an assistant professor of Dermatology and Dermatopathology, when she co-founded Naked Biome. She is an inventor with 2 granted patents, has published in notable journals such as Nature and the Journal of the American Academy of Dermatology, and is the author on more than 40 medical book chapters.

Rohit Vanjani is a Director and Equity Research Analyst covering the Specialty Pharmaceuticals sector at Guggenheim Securities. He has more than 10 years of Wall Street research experience in the health care sector. Prior to joining Guggenheim, Mr. Vanjani was a buy-side Therapeutics Analyst at Pura Vida Investments, a health care dedicated hedge fund. Previously, he was a Senior Analyst at Oppenheimer & Co., where he was named a “Rising Star” in the 2016 Institutional Investor All-America research poll in the Pharmaceuticals/Specialty category. He has held prior research roles at Jefferies, UBS and Leerink Swann, helping to cover the biotechnology, managed care, hospitals, and specialty pharmaceuticals verticals. He also has worked as an assistant economist at the Federal Reserve Bank of New York and as an economics associate at Stanford University, helping to conduct healthcare economic research.

Mr. Vanjani holds a BS in Biochemistry and Economics from the University of Michigan and an MBA from the NYU Stern School of Business.

Peter Aksel has been representing LEO Pharma in Silicon Valley since 2014 - scouting new health technologies and digital patient solutions within Dermatology. He is a board member at several digital health startups and is an industry advisor at Stanford School of Medicine. Prior to this, he was leading Global Patient Engagement at LEO Pharma, developing integrated care concepts and patient co-creation partnerships globally.

Peter Aksel is a health economist by training, and prior to joining the industry, researched medication non-adherence in dermatology. He is the co-founder of several companies, and an active board member and advisor to the Danish Government on the development of new educational innovation programs. He has recently relocated to Copenhagen, to take up a new position and extend his industry experience as Vice President and Head of Global Procurement.

Lee Zane, MD, MAS, FAAD, is a board-certified dermatologist and former Senior Vice-President and Chief Medical Officer (CMO) at Anacor, where he led the successful clinical development of the novel chemical entities, tavaborole (Kerydin) and crisaborole (Eucrisa). Prior to being CMO, he had served as Anacor’s Vice President of Clinical Development from August 2008 to October 2013 and had served as Medical Director at Anacor since January 2008. From 2003 to 2007, Dr. Zane served as Assistant Professor of Clinical Dermatology at the University of California, San Francisco (UCSF), Department of Dermatology, where he was the Director of Mt. Zion Dermatology Clinical Research Unit and the Director of the Acne Specialty Practice.

Dr. Zane received his B.A. from Colgate University and his M.D. from Stanford University. He completed his Dermatology residency training at the University of California, San Francisco, where he also earned a Master's of Advanced Studies in Clinical Research and maintains a faculty position as Assistant Clinical Professor of Dermatology and Epidemiology and Biostatistics at UCSF.